<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102350">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01690260</url>
  </required_header>
  <id_info>
    <org_study_id>N-20040019</org_study_id>
    <nct_id>NCT01690260</nct_id>
  </id_info>
  <brief_title>Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment</brief_title>
  <official_title>Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Orthopaedic Division, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Clinical and Basic Research (CCBR A/S).</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern Orthopaedic Division, Denmark</source>
  <oversight_info>
    <authority>Denmark: The Danish National Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Results of growth factors indicate that Bone Morphogenetic Proteins (BMP) have an
      exceptional ability to stimulate different characteristics of mesenchymale cells to osseous
      cells. Local application of BMP results in an increase of osseous tissue regardless of the
      location of the growth factor.

      5 years clinical studies show that BMP's can stimulate an increase of osseous tissue and
      improve clinical results when autologous bone graft is reduced or removed.

      The purpose of this study is to examine whether recombinant growth factor BMP-2 can replace
      autologous bone graft in order to stimulating ossification  during transplantation of
      osseous tissue.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visible radiological signs of healing after 6 months.</measure>
    <time_frame>An expected average of 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiological signs of healing is a criteria for a successful result.
Failure of healing after 6 months and/or a need for stimulant bone healing intervention can result in:
Dynamic measurement af immobilization
Ultrasound stimulation
Re-surgery with application of bone graft or bone replacement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serologic bone markers</measure>
    <time_frame>An expected average of 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood tests will be analyzed 1,2,3,4,6,9 and 12 months after operation in order to registrating a change in serologic bone markers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bone Degenerative Changes</condition>
  <condition>Osteoarthritis</condition>
  <condition>Degenerative Disorder of Bone</condition>
  <arm_group>
    <arm_group_label>Bone Morphogenetic Protein 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous bone graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bone Morphogenetic Protein 2</intervention_name>
    <description>12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.</description>
    <arm_group_label>Bone Morphogenetic Protein 2</arm_group_label>
    <arm_group_label>Autologous bone graft</arm_group_label>
    <other_name>No other names.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous bone graft</intervention_name>
    <description>Autologous bone graft in connection with bone docking operation.</description>
    <arm_group_label>Bone Morphogenetic Protein 2</arm_group_label>
    <arm_group_label>Autologous bone graft</arm_group_label>
    <other_name>No other names.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalised for autologous bone graft based on Ilizarow treatment.

          -  Age between 20 and 70 years.

        Exclusion Criteria:

          -  Rheumatoid osteoarthritis

          -  Malignant disease

          -  Current hormone treatment (glucocorticoid, parathyreoidea, thyreoidea)

          -  Pregnancy

          -  Abuse of drugs and alcohol

          -  Need of long-term NSAID treatment

          -  Breastfeeding women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knud S. Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopaedic Surgery Research Unit, Aalborg University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Donnell, Advisor</last_name>
    <role>Study Chair</role>
    <affiliation>Medtronic Inc., Watford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans H. Hoeck, MD, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Clinical and Basic Research, Aalborg, Denmark (CCBR A/S)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Knud Christensen, MD</last_name>
    <phone>99322595</phone>
    <phone_ext>45</phone_ext>
    <email>knsc@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sten Rasmussen, MD</last_name>
    <phone>99322367</phone>
    <phone_ext>45</phone_ext>
    <email>sten.rasmussen@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orthopaedic Surgery Research Unit, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knud S. Christensen, MD</last_name>
      <phone>99322595</phone>
      <phone_ext>45</phone_ext>
      <email>knsc@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Susanne Joelck, Nurse</last_name>
      <phone>99322608</phone>
      <phone_ext>45</phone_ext>
      <email>s.joelck@rn.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Knud S. Christensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanne Joelck, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>September 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone</keyword>
  <keyword>Morphogenetic</keyword>
  <keyword>Protein</keyword>
  <keyword>Ilizarow</keyword>
  <keyword>Autologous</keyword>
  <keyword>Osteoarthritis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
